MOLECULAR ANALYSIS OF APICAL ORGANELLES OF PLASMODIUM
疟原虫顶端细胞器的分子分析
基本信息
- 批准号:2442531
- 负责人:
- 金额:$ 11.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-07-01 至 1999-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Plasmodium merozoite actively enter host erythrocytes by a complex but
poorly understood invasion process. Molecules from the micronemes, an
organelle of the merozoite apical complex, appear to facilitate parasite
invasion by binding to specific receptors on the erythrocyte's surface.
Different Plasmodium species use different erythrocyte receptors, but
these parasite molecules which recognize the different receptors are
genetically related. Members of this family of erythrocyte binding
proteins, herein termed merozoite Microneme Protein-1 (MP-1), include the
P. vivax and P. knowlesi Duffy binding protein family and the P.
falciparum sialic acid binding protein (EBA175). These proteins have
intrinsic interest for their biological function and also because
antibody to the EBP175 has been shown to inhibit parasite development.
Identification of conserved and immunogenic regions of these proteins
which induce an inhibitory immune response will be important for the
development of an asexual stage malaria vaccine.
Genetic analysis of the MP-1 gene family is necessary to identify
conserved and polymorphic regions. Towards this goal I have examined
laboratory strains of P. knowlesi and field isolates of P. vivax. I have
identified polymorphisms in the MP-1 genes of both species. I propose
to further characterize polymorphism in field isolates of P. vivax in
order to determine if the vivax MP-1 has more than one allele and to
identify conserved and polymorphic regions of the MP-1. Laboratory
models for the study of the MP-1 family will be established using the
rodent malaria parasites P. berghei and P. yoelii. The MP-1 genes of P.
berghei and P. yoelii have been identified in my laboratory and will be
cloned and characterized. The MP-1 genes of P. vivax, P. berghei and P.
voelii will be expressed as recombinant proteins and used to assay immune
reactions to MP-1 in their respective hosts. Full length and separate
regions of the MP-1 will be expressed as recombinant proteins and tested
for growth inhibition in vaccinated animals. Monoclonal antibodies will
be produced against the P. berhei MP-1 for use in characterizing
immunogenic epitopes and functional regions. The experiments outlined
in this proposal will help identify and characterize the essential
functional regions of these important erythrocyte binding proteins so
they can be developed as effective vaccines.
疟原虫通过复合物积极进入宿主红细胞
了解入侵过程还差。 来自微分子的分子,一个
Merozoite顶端综合体的细胞器似乎有助于寄生虫
通过与红细胞表面上的特定受体结合来侵袭。
不同的疟原虫使用不同的红细胞受体,但
这些识别不同受体的寄生虫分子是
遗传相关。 这个红细胞结合的家族的成员
蛋白质(以下称为梅罗唑岩微生物蛋白-1(MP-1))包括
P. vivax和P. knowlesi duffy结合蛋白家族和P.
恶性唾液酸结合蛋白(EBA175)。 这些蛋白质具有
其生物学功能的内在兴趣,也是因为
对EBP175的抗体已显示可抑制寄生虫的发育。
鉴定这些蛋白质的保守和免疫原状区域
诱导抑制免疫反应对
开发无性阶段疟疾疫苗。
MP-1基因家族的遗传分析对于鉴定是必要的
保守和多态区域。 对于这个目标,我已经检查了
P. knowlesi的实验室菌株和Vivax的田间分离株。 我有
在这两种物种的MP-1基因中鉴定出多态性。 我建议
为了进一步表征假霉菌的田间分离株中的多态性
为了确定Vivax MP-1是否具有多个等位基因和
确定MP-1的保守和多态区域。 实验室
使用MP-1家族的研究模型将使用
啮齿动物疟疾寄生虫P. Berghei和P. Yoelii。 P.的MP-1基因
Berghei和P. Yoelii已在我的实验室中确定,将是
克隆和特征。 Vivax,P。Berghei和P.的MP-1基因
VOELII将表示为重组蛋白,用于测定免疫
在其各自宿主中对MP-1的反应。 全长,分开
MP-1的区域将表示为重组蛋白并测试
用于疫苗接种动物的生长抑制作用。 单克隆抗体会
使用P. berhei MP-1生产以用于表征
免疫原性表位和功能区域。 实验概述了
在此提案中,将有助于识别和表征必不可少的
这些重要的红细胞结合蛋白的功能区域
它们可以作为有效的疫苗开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
John H Adams的其他基金
Accelerating discovery of an efficacious Plasmodium vivax multivalent multi-stage vaccine
加速发现有效的间日疟原虫多价多阶段疫苗
- 批准号:1030753010307530
- 财政年份:2020
- 资助金额:$ 11.33万$ 11.33万
- 项目类别:
Evaluation of ivermectin as an antimalarial therapy against P. falciparum liver stage
伊维菌素抗疟治疗恶性疟原虫肝期的评价
- 批准号:1000170510001705
- 财政年份:2020
- 资助金额:$ 11.33万$ 11.33万
- 项目类别:
Plasmodium ovale hypnozoite development and relapse: a coordinated in vivo in vitro study
卵形疟原虫休眠子的发育和复发:体内体外协调研究
- 批准号:1030420310304203
- 财政年份:2020
- 资助金额:$ 11.33万$ 11.33万
- 项目类别:
Accelerating discovery of an efficacious Plasmodium vivax multivalent multi-stage vaccine
加速发现有效的间日疟原虫多价多阶段疫苗
- 批准号:1052642210526422
- 财政年份:2020
- 资助金额:$ 11.33万$ 11.33万
- 项目类别:
Evaluation of ivermectin as an antimalarial therapy against P. falciparum liver stage
伊维菌素抗疟治疗恶性疟原虫肝期的评价
- 批准号:1017029510170295
- 财政年份:2020
- 资助金额:$ 11.33万$ 11.33万
- 项目类别:
Discovering the essential genome of Plasmodium falciparum
发现恶性疟原虫的基本基因组
- 批准号:1016471010164710
- 财政年份:2018
- 资助金额:$ 11.33万$ 11.33万
- 项目类别:
Chemogenomic Profiling of Plasmodium Falciparum Responses and Resistance
恶性疟原虫反应和耐药性的化学基因组学分析
- 批准号:1031774710317747
- 财政年份:2015
- 资助金额:$ 11.33万$ 11.33万
- 项目类别:
Chemogenomic Profiling of Plasmodium Falciparum Responses and Resistance
恶性疟原虫反应和耐药性的化学基因组学分析
- 批准号:1044935410449354
- 财政年份:2015
- 资助金额:$ 11.33万$ 11.33万
- 项目类别:
Chemogenomic Profiling of Plasmodium falciparum Drug Responses and Resistance
恶性疟原虫药物反应和耐药性的化学基因组学分析
- 批准号:88649568864956
- 财政年份:2015
- 资助金额:$ 11.33万$ 11.33万
- 项目类别:
Chemogenomic Profiling of Plasmodium falciparum Drug Responses and Resistance
恶性疟原虫药物反应和耐药性的化学基因组学分析
- 批准号:92061379206137
- 财政年份:2015
- 资助金额:$ 11.33万$ 11.33万
- 项目类别:
相似海外基金
Malaria antigens binding to band 3 in red cell invasion
疟疾抗原与红细胞侵袭中的带 3 结合
- 批准号:67290966729096
- 财政年份:2003
- 资助金额:$ 11.33万$ 11.33万
- 项目类别:
Malaria antigens binding to band 3 in red cell invasion
疟疾抗原与红细胞侵袭中的带 3 结合
- 批准号:65991786599178
- 财政年份:2003
- 资助金额:$ 11.33万$ 11.33万
- 项目类别:
ERYTHROCYTE ADHESION IN FALCIPARUM MALARIA
恶性疟疾中的红细胞粘附
- 批准号:63498706349870
- 财政年份:2000
- 资助金额:$ 11.33万$ 11.33万
- 项目类别:
ERYTHROCYTE ADHESION IN FALCIPARUM MALARIA
恶性疟疾中的红细胞粘附
- 批准号:66278756627875
- 财政年份:2000
- 资助金额:$ 11.33万$ 11.33万
- 项目类别:
ERYTHROCYTE ADHESION IN FALCIPARUM MALARIA
恶性疟疾中的红细胞粘附
- 批准号:64971136497113
- 财政年份:2000
- 资助金额:$ 11.33万$ 11.33万
- 项目类别: